{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:00:51Z","timestamp":1790586051299,"version":"4.1.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>B7-H3 (CD276), a member of the B7 family of immunoregulatory ligands, has emerged as an important molecule at the intersection of tumor biology and cancer immunology. Although initially identified as a regulator of T-cell responses, accumulating evidence supports its predominantly immunosuppressive role. B7-H3 is highly expressed across diverse malignancies, including brain, prostate, lung, breast, colorectal, and pediatric cancers, while showing limited expression in most normal adult tissues. Its tumor-associated expression, including tumor vasculature, makes B7-H3 an attractive therapeutic target. Beyond immune regulation, B7-H3 promotes tumor progression through tumor cell-intrinsic mechanisms involving PI3K\/AKT, NF-\u03baB, and STAT3 signaling, angiogenesis, epithelial-to-mesenchymal plasticity, and metabolic reprogramming. Within the tumor microenvironment, B7-H3 suppresses T-cell and natural killer cell activity and promotes immunosuppressive macrophage polarization, while its expression can be regulated by metabolic and epigenetic mechanisms. These multifaceted functions have stimulated the development of diverse B7-H3-targeted therapies, including monoclonal antibodies, antibody-drug conjugates, CAR T-cell and V\u03b41 T-cell therapies, nanobody-based platforms, and bispecific or trispecific immune cell engagers. Early clinical studies have demonstrated promising antitumor activity, although important challenges regarding efficacy, safety, tumor heterogeneity, and patient selection remain. In this review, we summarize the molecular regulation and biological functions of B7-H3, critically evaluate the current development of B7-H3-targeted therapies, and discuss key challenges and future directions for translating B7-H3-directed strategies into effective cancer treatments.<\/jats:p>","DOI":"10.3389\/fphar.2026.1953747","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:52:03Z","timestamp":1790585523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["B7-H3-mediated immune regulation in cancer: biological functions and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Shreya","family":"Shreshtha","sequence":"first","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasini","family":"Kaluarachchige","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia A.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil S.","family":"Basnyat","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cell and Cancer Biology, The University of Toledo College of Medicine and Life Sciences","place":["Toledo, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3390\/cancers15133530","article-title":"B7-H3 associates with IMPDH2 and regulates cancer cell survival","volume":"15","author":"Alhamad","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115838","DOI":"10.1016\/j.intimp.2025.115838","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors: a review of the intricate mechanisms and potential strategies","volume":"168","author":"Arora","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1495283","DOI":"10.3389\/fimmu.2024.1495283","article-title":"B7-H3 in glioblastoma and beyond: significance and therapeutic strategies","volume":"15","author":"Babic","year":"2024","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/pin.12999","article-title":"High B7-H3 expression is linked to increased risk of prostate cancer progression","volume":"70","author":"Bonk","year":"2020","journal-title":"Pathol. Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1523338","DOI":"10.1155\/2022\/1523338","article-title":"B7-H3: a useful emerging diagnostic marker for colon cancer","volume":"2022","author":"Bostanci","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers15133279","article-title":"B7-H3 in pediatric tumors: far beyond neuroblastoma","volume":"15","author":"Bottino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e007174","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"104077","DOI":"10.1016\/j.cellimm.2020.104077","article-title":"B7-H3: a promising therapeutic target for autoimmune diseases","volume":"352","author":"Chen","year":"2020","journal-title":"Cell Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.7150\/jca.91089","article-title":"Dual inhibition of B7-H3 and EGFR overcomes acquired chemoresistance in colon adenocarcinoma","volume":"15","author":"Chen","year":"2024","journal-title":"J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114298","DOI":"10.1016\/j.bcp.2020.114298","article-title":"B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy","volume":"183","author":"Cheng","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fonc.2018.00264","article-title":"B7H3 as a promoter of metastasis and promising therapeutic target","volume":"8","author":"Dong","year":"2018","journal-title":"Front. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e009710","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101801","DOI":"10.1016\/j.tranon.2023.101801","article-title":"B7-H3\/CD276 and small-cell lung cancer: what's new?","volume":"39","author":"Fabrizio","year":"2024","journal-title":"Transl. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1007\/s00432-023-04790-3","article-title":"Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer","volume":"149","author":"Fan","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-025-07646-1","article-title":"Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances","volume":"24","author":"Fatahichegeni","year":"2025","journal-title":"J. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"108153","DOI":"10.1016\/j.intimp.2021.108153","article-title":"The role of B7-H3 in tumors and its potential in clinical application","volume":"101","author":"Feng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.36401\/jipo-23-18","article-title":"B7-H3 inhibitors in oncology clinical trials: a review","volume":"7","author":"Feustel","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 immune checkpoint protein in human cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.21037\/jgo-21-821","article-title":"A three-phase trans-ethnic study reveals B7-H3 expression is a significant and independent biomarker associated with colon cancer overall survival","volume":"12","author":"Gao","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.7150\/ijbs.85813","article-title":"B7-H3 in brain malignancies: immunology and immunotherapy","volume":"19","author":"Guo","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur. Urol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/itt.s507522","article-title":"Tumor immunotherapy targeting B7-H3: from mechanisms to clinical applications","volume":"14","author":"Guo","year":"2025","journal-title":"Immunotargets Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"152420","DOI":"10.1016\/j.prp.2019.04.012","article-title":"B7-H3 and its role in bone cancers","volume":"215","author":"He","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1391954","DOI":"10.3389\/fimmu.2024.1391954","article-title":"The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas","volume":"15","author":"Holzmayer","year":"2024","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/jgo-24-384","article-title":"B7-H3 enhances colorectal cancer progression by regulating HB-EGF via HIF-1alpha","volume":"15","author":"Hu","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e010083","DOI":"10.1136\/jitc-2024-010083","article-title":"Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study","volume":"13","author":"Inthanachai","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10555-025-10294-y","article-title":"B7-H3 in the tumor microenvironment: implications for CAR T cell therapy in pediatric solid tumors","volume":"44","author":"Jansen","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/0008-5472.can-24-0195","article-title":"B7-H3-targeted CAR-Vdelta1T cells exhibit potent broad-spectrum activity against solid tumors","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12885-024-11933-3","article-title":"A promising target for breast cancer: B7-H3","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e010924","DOI":"10.1136\/jitc-2024-010924","article-title":"Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer","volume":"13","author":"Jiang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B37","first-page":"13987","article-title":"B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer","volume":"8","author":"Jin","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.3390\/ijms25073976","article-title":"B7-H3 expression in breast cancer and brain metastasis","volume":"25","author":"Joshi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101207","DOI":"10.1016\/j.drup.2025.101207","article-title":"B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer","volume":"79","author":"Ju","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"B40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/brainsci15080872","article-title":"B7-H3 as a reliable diagnostic biomarker for the differentiation of high-grade gliomas (HGGs) and low-grade gliomas (LGGs)","volume":"15","author":"Jukovi\u0107-Bihorac","year":"2025","journal-title":"Brain Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e011370","DOI":"10.1136\/jitc-2024-011370","article-title":"Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer","volume":"13","author":"Khaw","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/pai.0000000000001001","article-title":"Comparison of the clinicopathologic features and T-Cell infiltration of B7-H3 and B7-H4 expression in triple-negative breast cancer subtypes","volume":"30","author":"Kim","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vaccines12010054","article-title":"New emerging targets in cancer immunotherapy: the role of B7-H3","volume":"12","author":"Koumprentziotis","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/itt.s534666","article-title":"B7-H3\/CD276: novel immune checkpoint and jack of all trades","volume":"14","author":"Larkin","year":"2025","journal-title":"Immunotargets Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.ccr-20-2540","article-title":"Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"757047","DOI":"10.3389\/fimmu.2021.757047","article-title":"Multi-omics data analyses identify B7-H3 as a novel prognostic biomarker and predict response to immune checkpoint blockade in head and neck squamous cell carcinoma","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00262-021-03097-x","article-title":"Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/biomedicines13092130","article-title":"Comparative preclinical analysis of Anti-B7-H3 CAR-T cells targeting neuroblastoma","volume":"13","author":"Lutskovich","year":"2025","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","article-title":"B7-H3 is widely expressed in soft tissue sarcomas","volume":"24","author":"Lynch","year":"2024","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.7150\/thno.105947","article-title":"Histone lactylation-driven B7-H3 expression promotes tumor immune evasion","volume":"15","author":"Ma","year":"2025","journal-title":"Theranostics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.3892\/ol.2017.6935","article-title":"Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma","volume":"14","author":"Mao","year":"2017","journal-title":"Oncol. Lett."},{"key":"B60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14712598.2021.1862791","article-title":"B7-H3 targeted antibody-based immunotherapy of malignant diseases","volume":"21","author":"Michelakos","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/cells14151209","article-title":"B7-H3 in cancer immunotherapy-prospects and challenges: a review of the literature","volume":"14","author":"Mielcarska","year":"2025","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.cir-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"114890","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2019.08.030","article-title":"B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres","volume":"47","author":"Nehama","year":"2019","journal-title":"EBioMedicine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1612186","DOI":"10.3389\/pore.2025.1612186","article-title":"B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment","volume":"31","author":"Ott","year":"2025","journal-title":"Pathol. Oncol. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3390\/cancers17091546","article-title":"The attractiveness of B7-H3 as a target for lung cancer treatment","volume":"17","author":"Papavassiliou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.clcc.2025.09.005","article-title":"B7-H3 in colorectal adenocarcinoma: are we focusing on the right target?","volume":"24","author":"Parente","year":"2025","journal-title":"Clin. Colorectal Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"101580","DOI":"10.1016\/j.tranon.2022.101580","article-title":"Hopes on immunotherapy targeting B7-H3 in neuroblastoma","volume":"27","author":"Pulido","year":"2023","journal-title":"Transl. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2024.05.003","article-title":"B7-H3: a robust target for immunotherapy in prostate cancer","volume":"10","author":"Pulido","year":"2024","journal-title":"Trends Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1829359","DOI":"10.3389\/fimmu.2026.1829359","article-title":"The B7-H3\/CD3 immune phenotype identifies prognostic subgroups in neuroblastoma","volume":"17","author":"Rasic","year":"2026","journal-title":"Front. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.dist.2026.100012","article-title":"Next-generation CAR-T combinations: integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting","volume":"2","author":"Sharma","year":"2026","journal-title":"Dis. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2026.04.001","article-title":"Repurposing payloads: next generation of antibody-drug conjugates","volume":"12","author":"Shatzer","year":"2026","journal-title":"Trends Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12672-024-01674-x","article-title":"Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer","volume":"15","author":"Shen","year":"2024","journal-title":"Discov. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41698-022-00323-2","article-title":"Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer","volume":"6","author":"Shi","year":"2022","journal-title":"Npj Precis. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1857767","DOI":"10.3389\/fimmu.2026.1857767","article-title":"B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies","volume":"17","author":"Smith","year":"2026","journal-title":"Front. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13000-024-01504-2","article-title":"B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma","volume":"19","author":"Song","year":"2024","journal-title":"Diagn. Pathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","article-title":"Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma","volume":"16","author":"Song","year":"2025","journal-title":"Nat. Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e011533","DOI":"10.1136\/jitc-2025-011533","article-title":"B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer","volume":"13","author":"Stucchi","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1097\/cm9.0000000000003099","article-title":"B7-H3 in acute myeloid leukemia: from prognostic biomarker to immunotherapeutic target","volume":"137","author":"Tan","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1472626","DOI":"10.3389\/fimmu.2024.1472626","article-title":"Immunoregulatory protein B7-H3 upregulated in bacterial and viral infection and its diagnostic potential in clinical settings","volume":"15","author":"Tigabu","year":"2024","journal-title":"Front. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/neuonc\/noag025","article-title":"Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma","volume":"28","author":"Timpanaro","year":"2026","journal-title":"Neuro. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1182\/blood.2021014671","article-title":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","volume":"139","author":"Tyagi","year":"2022","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1193963","DOI":"10.3389\/fonc.2023.1193963","article-title":"B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers","volume":"13","author":"Ventin","year":"2023","journal-title":"Front. Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.cd-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"B88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41419-020-2252-3","article-title":"B7-H3 promotes colorectal cancer angiogenesis through activating the NF-kappaB pathway to induce VEGFA expression","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"110737","DOI":"10.1016\/j.cellsig.2023.110737","article-title":"Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1\/mTOR\/VEGFA pathway","volume":"109","author":"Wu","year":"2023","journal-title":"Cell Signal"},{"key":"B90","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12879-023-08411-9","article-title":"Clinical significance of B7-H3 expression in circulating CD4(+)CD25(high) T cells, CD14(+) monocytes, and plasma for the progression of HIV infection","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B92","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1535-7163.mct-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-Based antibody-drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2020.03.033","article-title":"Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer","volume":"133","author":"Yim","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/brainsci15020212","article-title":"Prognostic biomarkers in isocitrate dehydrogenase wild-type glioblastoma: a focus on B7-H3","volume":"15","author":"Y\u00fcceer","year":"2025","journal-title":"Brain Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3892\/or.2017.5858","article-title":"B7-H3 is related to tumor progression in ovarian cancer","volume":"38","author":"Zhang","year":"2017","journal-title":"Oncol. Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","article-title":"B7-H3-Targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"7831","DOI":"10.1002\/cam4.4284","article-title":"Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1586759","DOI":"10.3389\/fimmu.2025.1586759","article-title":"Research progress of B7-H3 in malignant tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1038\/s41598-026-40855-2","article-title":"sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes","volume":"16","author":"Zhao","year":"2026","journal-title":"Sci. Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J. Neurooncol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1953747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:52:04Z","timestamp":1790585524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1953747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":102,"alternative-id":["10.3389\/fphar.2026.1953747"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1953747","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1953747"}}